Glucagon-Like Peptide-1 (GLP-1) Analogs Product description The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Analogs as of November 2008 provides a competitor analysis in the development pipeline of novel GLP-1 Analogs and GLP-1 receptor agonists for treatment of type 2 diabetes. Binding of glucagon-like peptide-1 (GLP-1) analogs or agonists to the GLP receptor induces insulin secretion from pancreatic beta cells. Exendin (Byetta) is the first representative of this new class of incretin mimetics, first approved in 2005 for treatment of type 2 diabetes. Byetta sales in the first nine months of 2008 increased by 22 % to US$ 565 mln (vs 9-mth period of previous year). While Byetta requires twice-daily subcutaneous injections, closest competitor GLP-1 analogs already filed for registration or in phase III offer once-daily SC dosing and appear to be more effective in head-to-head comparison. Second generation GLP-1 analogs allow less frequent SC administration due to drug delivery, pegylation or genetic engineering technologies. At least seven different long-acting GLP-1 analog molecules are currently in clinical development and at least further seven in advanced preclinical stages. A third generation of GLP-1 analogs and GLP-1 receptor agonists with oral administration is emerging. The first two orally delivered GLP-1 mimetics (one analog, one agonist) are already undergoing clinical development, further at least eight different compounds are in preclinical R&D. Traditional drug delivery solutions for non-injectable administration of GLP-1 mimetics, such as inhalation or nasal administration, are a minority approach. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index - GLP-1 Analogs with Daily Injection
- Long-Acting Injectable GLP-1 Analogs
- Oral GLP-1 Analogs
- Other Non-Injectable GLP-1 Analogs
- GLP-1 Analogs for Other Indications
- Corporate GLP-1 Analog R&D Pipelines
- About La Merie
Corporate GLP-1 Analog R&D Pipelines - Addex Pharmaceuticals
- Amylin Pharmaceuticals
- Arisaph Pharmaceuticals
- Arisgen
- Ascendis Pharma (Complex Biosystems)
- Bio-ker
- Biocompatibles International
- ConjuChem
- Dong-A Pharmaceutical
- Eli Lilly
- Emisphere Technologies
- Faust Pharmaceuticals
- GlaxoSmithKline
- Hanmi Pharmaceuticals
- Ipse
- Mannkind
- MDRNA (ex Nastech Pharmaceuticals)
- Modigene
- Novo Nordisk
- OctoPlus
- Oramed Pharmaceuticals
- Pfizer
- Proxima Concepts
- Roche (& Chugai)
- Rose Pharmaceuticals (ex Gastrotech)
- Sanofi-Aventis
- Teijin
- Transition Therapeutics
- TransTech Pharma
- Unigene
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
